NCT07147114尚未招募4 期
A Multicenter, Randomized, Double-Blind, Exploratory Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 64
- 试验地点
- 15
- 主要终点
- Hierarchical outcome component(Change in PVR, Change in NT-proBNP, Change in 6MWD, Change in KCCQ-CSS)
研究概览
简要总结
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
The study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks.
Participants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •<Screening Visit (Visit 1)>
- •A male or female adults aged 19 years or older in South Korea
- •LVEF greater than 40% on echocardiogram performed within 12 weeks prior to screening
- •Presence of heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) accompanied by combined pre- and post-capillary pulmonary hypertension (CpcPH)
- •Meeting all of the following criteria on RHC performed within 48 weeks prior to screening:
- •mPAP > 20 mmHg
- •PVR > 2 Wood units (WU)
- •PAWP > 15 mmHg
- •World Health Organization Functional Class (WHO-FC) II or III at the time of screening
- •If taking any of the following medications at the time of screening, the participant must have been on a stable dose for at least 3 months:
- •Renin-angiotensin system inhibitors
- •Beta-blockers
- •Mineralocorticoid receptor antagonists (aldosterone antagonists)
- •Sodium-glucose cotransporter-2 (SGLT2) inhibitors
- •<Baseline Visit (Visit 2)>
- •1. World Health Organization Functional Class (WHO-FC) II or III at the time of baseline visit
排除标准
- •<Screening Visit (Visit 1)>
- •Known hypersensitivity to the active ingredients (Macitentan, Dapagliflozin) or any excipients of the investigational medicinal product
- •Pregnant or breastfeeding women, or those who do not agree to use at least two appropriate contraceptive methods* (self or partner) during the clinical trial period and for 30 days after the last administration of the investigational medicinal product (for male participants, those who do not agree to refrain from sperm donation)
- •*: a. Surgical sterilization (e.g., vasectomy) or intrauterine device (IUD; copper IUD or hormone-releasing intrauterine system), b. Non-oral hormonal contraceptive or spermicide in combination with a barrier method, c. Cervical cap or diaphragm used in combination with a male condom.
- •Participants with type 1 diabetes mellitus or secondary diabetes mellitus
- •Participants with metabolic acidosis, such as diabetic ketoacidosis
- •Participants diagnosed with pulmonary hypertension other than WHO Group 2 pulmonary hypertension (i.e., WHO Group 1, 3, 4, or 5)
- •Group 1: Pulmonary arterial hypertension
- •Group 3: Pulmonary hypertension associated with lung diseases and/or hypoxia
- •Group 4: Chronic thrombo-embolic pulmonary hypertension
- •Group 5: Pulmonary hypertension with unclear and/or multifactorial mechanisms
- •Participants who meet the following criteria on RHC performed within 48 weeks prior to screening:
- •a. PAWP ≤ 15 mmHg
- •History of taking any of the following medications within 4 weeks prior to screening:
- •Calcium channel blockers
- •Endothelin receptor antagonists
- •Phosphodiesterase type 5 inhibitors (PDE5i)
- •Riociguat, Vericiguat
- •Prostacyclin (PC) analogs or prostacyclin receptor agonists
- •Activin signaling inhibitors
- •History of any of the following medical conditions, surgeries, or procedures:
- •Myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention (PCI) within 3 months prior to screening
- •Uncontrolled tachycardia (>110 bpm) due to atrial fibrillation or atrial flutter
- •History of heart transplantation or implantation of a ventricular assist device, or planned to undergo such procedures
- •eGFR ≤ 30 mL/min/1.73 m² or AST or ALT ≥ 2.5 × ULN
- •Urinary tract infection, genital infection (including fungal infections), or voiding disorder within 24 weeks prior to screening
- •Hemoglobin < 9 g/dL at the time of screening
- •Participants with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •Known hypersensitivity to soybean oil or history of soybean oil allergy
- •Known hypersensitivity to soy or peanuts
- •Participation in another clinical trial involving administration/application of an investigational medicinal product or medical device within 3 months prior to screening
- •<Baseline Visit (Visit 2)>
- •Participants who, upon re-confirmation of inclusion/exclusion criteria at the baseline visit, have any disqualifying condition
- •Any other condition that, in the opinion of the investigator, makes the participant unsuitable for participation in this clinical trial
研究组 & 干预措施
Combination therapy group
Experimental
Maciten Tab. 10mg
干预措施: Combination therapy (Drug)
Monotherapy group
Placebo Comparator
Dapozin Tab. 10mg or 5mg
干预措施: Monotherapy (Drug)
结局指标
主要结局
Hierarchical outcome component(Change in PVR, Change in NT-proBNP, Change in 6MWD, Change in KCCQ-CSS)
时间窗: Baseline, 24 week
The hierarchical composite variable includes the rate of change in Pulmonary Vascular Resistance (PVR), NT-proBNP, change in 6-minute walk distance, and change in KCCQ-CSS score. All possible pairwise comparisons between combination therapy group and monotherapy group subjects (e.g., 2 subjects in combination group and 3 in monotherapy group yield 6 pairs) are classified as Win, Loss, or Tie based on the following definitions. If the subject in the pair meeting the criteria belongs to the combination group, it is evaluated as a Win; if in the monotherapy group, a Loss.
次要结局
- Change in Pulmonary Vascular Resistance (PVR) from Baseline to Week 24(Baseline, 24 week)
- Change in Mean Pulmonary Arterial Pressure (mPAP) from Baseline to Week 24(Baseline, 24 week)
- Change in Pulmonary Arterial Wedge Pressure (PAWP) from Baseline to Week 24(Baseline, 24 week)
- Change in 6-Minute Walk Distance from Baseline to Week 24(Baseline, 24 week)
- Change in Oxygen Saturation (SpO2) Difference Before and After 6-Minute Walk Test from Baseline to Week 24(Baseline, 24 week)
- Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) from Baseline to Week 24(Baseline, 24 week)
- Change in Tricuspid Regurgitation Velocity (TRV) from Baseline to Week 24(Baseline, 24 week)
- Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) from Baseline to Week 24(Baseline, 24 week)
- Use of Intravenous Diuretics During Treatment Period (Visit 2 to Visit 4)(Baseline, 24 week)
- Rate of Hospitalization Due to Heart Failure During Treatment Period (Visit 2 to Visit 4)(Baseline, 24 week)
- Number of Days Hospitalized for Heart Failure During Treatment Period (Visit 2 to Visit 4)(Baseline, 24 week)
- Number of Deaths (Cardiovascular and All-Cause) During Treatment Period (Visit 2 to Visit 4)(Baseline, 24 week)
- Change in Mean Right Atrial Pressure (mRAP) from Baseline to Week 24(Baseline, 24 week)
- Change in Cardiac Index (CI) from Baseline to Week 24(Baseline, 24 week)
- Change in Mixed Venous Oxygen Saturation (SvO2) from Baseline to Week 24(Baseline, 24 week)
- Change in Left Atrial Volume Index (LAVI) from Baseline to Week 24(Baseline, 24 week)
- Change in Tricuspid Valve Systolic Tissue Velocity (TV S' velocity) from Baseline to Week 24(Baseline, 24 week)
- Change in Right Atrial Area (RA area) from Baseline to Week 24(Baseline, 24 week)
- Change in Presence of Pericardial Effusion from Baseline to Week 24(Baseline, 24 week)
- Change in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) from Baseline to Week 24(Baseline, 24 week)
研究者
Wook-Jin Chung
Principal Investigator
Gachon University Gil Medical Center
研究点 (15)
Loading locations...
相似试验
已完成
2 期
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal ImpairmentDiabetes Mellitus, Type 2NCT00663260AstraZeneca631
Unknown
4 期
Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2Hypoglycemic EpisodesDiabetes MellitusNCT02719756Research Clinical Centre of the Russian Railways, JSC100
已完成
3 期
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and ExerciseType 2 DiabetesNCT00528372AstraZeneca1,067
已完成
2 期
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDType 2 Diabetes Mellitus, CKD and AlbuminuriaNCT02547935AstraZeneca459
已完成
3 期
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02413398AstraZeneca321